tiprankstipranks
Biotech Alert: Searches spiking for these stocks today
The Fly

Biotech Alert: Searches spiking for these stocks today

Stay ahead of biotech stocks seeing a surge in interest from retail and financial professional investors with this exclusive recap from The Fly

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: 

  • Hookipa Pharma (HOOK), 5,519% surge in interest
  • Fulcrum Therapeutics (FULC), 182% surge in interest
  • Cabaletta Bio (CABA), 160% surge in interest
  • Aurinia Pharm (AUPH), 127% surge in interest
  • Corbus Pharma (CRBP), 103% surge in interest

Pipeline and key clinical candidates for these companies:

Hookipa Pharma is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. Hookipa’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Hookipa’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, prostate cancers, and other undisclosed programs.

Fulcrum Therapeutics is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy, or FSHD, and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. 

Cabaletta Bio is focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA platform encompasses chimeric antigen receptor T cells for autoimmunity and Cabaletta Bio’s proprietary chimeric autoantibody receptor T cells.

Aurinia Pharmaceuticals is focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the company introduced Lupkynis, which it notes is the first FDA-approved oral therapy dedicated for the treatment of adult patients with active lupus nephritis.

Corbus is an immunology company whose current pipeline includes anti-integrin monoclonal antibodies that block activation of TGFβ and small molecules that activate or inhibit the endocannabinoid system.

Recent news on these stocks:


October 20

Hookipa Pharma announced a strategic collaboration and license agreement with Roche (RHHBY) to develop HB-700 for KRAS-mutated cancers and a second undisclosed novel arenaviral immunotherapy. This represents HOOKIPA’s first oncology licensing collaboration. Through the collaboration, HOOKIPA will conduct research and early clinical development through Phase 1b for HB-700, a novel investigational arenaviral immunotherapy for the treatment of KRAS-mutated cancers. Upon the completion of the Phase 1b trial, Roche has the right to assume development responsibility and to commercialize licensed products across multiple indications upon approval.

In a regulatory filing, Fulcrum Therapeutics disclosed that on October 14 Fulcrum and Dr. Judith Dunn entered into a separation agreement subsequent to Dr. Dunn’s resignation from her position as president, research and development. "Dr. Dunn will remain employed with Fulcrum through January 3, 2023, and continue to provide biotechnology consulting services, including clinical development services, in a transitional capacity while Fulcrum continues its previously announced search for a Chief Medical Officer," the filing stated.


About “Biotech Alert”

The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.

This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 15-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.

This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.

Keywords: biotech, biotech sector, biotech alert, investingchannel, XBI, SPDR S&P Biotech ETF

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on RHHBY:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles